Genzyme Receives CRL from FDA on Lemtrada Application

Genzyme, a Sanofi company

, announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.